Form 4: Teva Pharmaceuticals: CEO Richard D. Francis Trades Shares

Teva Pharmaceuticals President and CEO Richard D. Francis reported transactions involving ordinary shares and restricted share units, including sales to cover tax obligations.

Summary

• Richard D. Francis, President and CEO of Teva Pharmaceutical Industries Ltd., engaged in transactions involving the company's ordinary shares and restricted share units (RSUs).
• On June 5, 2026, 13,043 restricted share units vested, and these were subsequently sold to cover tax withholding obligations, amounting to 6,153 shares at a price of $34.35 per share.
• Following these transactions, Francis beneficially owns 1,177,529 ordinary shares directly.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on November 14, 2025.
• Restricted share units were originally granted on June 5, 2025, with staggered vesting dates through June 5, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions are routine and executed under a pre-established plan for tax purposes, with no indication of a change in the executive's fundamental view of the company.

Positives

• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a structured and pre-determined approach to share sales.
• The sale of shares to cover tax withholding obligations is a standard and necessary procedure upon vesting of equity awards.

Negatives

• A portion of the CEO's vested equity was sold, which could be interpreted as a reduction in direct ownership, although it was for tax purposes.

Risks

• While not explicitly stated as a risk in this filing, significant insider selling, even if for tax purposes, can sometimes be perceived negatively by the market.
• The Rule 10b5-1 plan's effectiveness relies on its adherence to regulatory requirements and the absence of material non-public information at the time of adoption.

Future Outlook

The filing details the vesting schedule of restricted share units through June 5, 2029, indicating future potential equity awards and their planned release.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those by C-suite executives like CEOs, are closely watched by investors. The use of a Rule 10b5-1 plan is a common strategy for executives to manage their stock holdings in a way that avoids accusations of insider trading, demonstrating a commitment to compliance.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes does not directly impact the company's operations or financial health, but any insider selling can influence market perception.
• Management: The transaction reflects standard executive compensation practices and compliance with tax regulations.

Next Steps

• Continued vesting of remaining restricted share units on June 5, 2027, June 5, 2028, and June 5, 2029, with potential for further tax-related share sales.
• Monitoring of future Form 4 filings by Richard D. Francis for any additional transactions.

Key Dates

Keywords

Teva Pharmaceuticals, Richard D. Francis, Form 4, Insider Trading, Share Transactions, Restricted Share Units, Rule 10b5-1, Tax Withholding, Beneficial Ownership